{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T11:05:42Z","timestamp":1781780742325,"version":"3.54.5"},"reference-count":48,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T00:00:00Z","timestamp":1735344000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Africa Centres for Disease Control and Prevention (Africa CDC) through its Saving Lives and Livelihoods (SLL) program."},{"name":"Ministry of Health and Social Protection"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Infect Dis"],"DOI":"10.1186\/s12879-024-10345-9","type":"journal-article","created":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T19:20:50Z","timestamp":1735413650000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Immunologic assessment of the impact of SARS-CoV-2 vaccine booster doses on humoral immunity: a cross-sectional study in morocco"],"prefix":"10.1186","volume":"24","author":[{"given":"Karima","family":"Abounouh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raji","family":"Tajudeen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hind","family":"Majidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soad","family":"Redwane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oumaima","family":"Laazaazia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Safaa","family":"Aqillouch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed E. Ogwell","family":"Ouma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammed","family":"Abdulaziz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Merawi","family":"Aragaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mosoka Papa","family":"Fallah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Senga","family":"Sembuche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Serge","family":"Batcho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick","family":"Kabwe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth","family":"Gonese","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abdelhakim","family":"Ainahi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u2019hammed","family":"Sarih","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Kaseya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abderrahmane","family":"Maaroufi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sayeh","family":"Ezzikouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,28]]},"reference":[{"key":"10345_CR1","doi-asserted-by":"publisher","first-page":"2632010","DOI":"10.1177\/2632010X221075584","volume":"15","author":"S Islam","year":"2022","unstructured":"Islam S, Islam T, Islam MR. New Coronavirus Variants are Creating More Challenges to Global Healthcare System: A Brief Report on the Current Knowledge. Clin Pathol. 2022;15:2632010. https:\/\/doi.org\/10.1177\/2632010X221075584.","journal-title":"Clin Pathol"},{"key":"10345_CR2","unstructured":"T. W. H. O. (WHO), Naming the coronavirus disease (COVID-19) and the virus that causes it, 2020. [Online]. Available: https:\/\/www.who.int\/emergencies\/diseases\/novel-coronavirus-2019\/technical-guidance\/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it"},{"key":"10345_CR3","unstructured":"T. W. H. O. (WHO), WHO Coronavirus (COVID-19) Dashboard, 2024. [Online]. Available: https:\/\/covid19.who.int\/"},{"key":"10345_CR4","unstructured":"T. W. H. O. (WHO), Morocco: WHO Coronavirus Disease (COVID-19), 2024. [Online]. Available: https:\/\/covid19.who.int\/region\/emro\/country\/ma"},{"key":"10345_CR5","unstructured":"M. d. l. S. e. d. l. P. Sociale, Le Portail Officiel du Coronavirus au Maroc, 2024. [Online]. Available: http:\/\/www.covidmaroc.ma\/pages\/Accueilfr.aspx"},{"key":"10345_CR6","doi-asserted-by":"publisher","unstructured":"Wang R, Hozumi Y, Yin C, Wei GW. Mutations on COVID-19 diagnostic targets, Genomics, vol. 112, no. 6, pp. 5204\u20135213, Nov 2020, https:\/\/doi.org\/10.1016\/j.ygeno.2020.09.028","DOI":"10.1016\/j.ygeno.2020.09.028"},{"key":"10345_CR7","doi-asserted-by":"publisher","unstructured":"Polack FP et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med, 383, 27, pp. 2603\u201315, Dec 31 2020, https:\/\/doi.org\/10.1056\/NEJMoa2034577","DOI":"10.1056\/NEJMoa2034577"},{"key":"10345_CR8","doi-asserted-by":"publisher","unstructured":"Baden LR et al. Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med, 384, 5, pp. 403\u201316, Feb 4 2021, https:\/\/doi.org\/10.1056\/NEJMoa2035389","DOI":"10.1056\/NEJMoa2035389"},{"key":"10345_CR9","doi-asserted-by":"publisher","unstructured":"Brown CM et al. Outbreak of SARS-CoV-2 Infections, Including COVID-19 Vaccine Breakthrough Infections, Associated with Large Public Gatherings - Barnstable County, Massachusetts, July 2021. MMWR Morb Mortal Wkly Rep, 70, 31, pp. 1059\u201362, Aug 6 2021, https:\/\/doi.org\/10.15585\/mmwr.mm7031e2","DOI":"10.15585\/mmwr.mm7031e2"},{"key":"10345_CR10","doi-asserted-by":"publisher","unstructured":"Pilishvili T et al. Effectiveness of mRNA Covid-19 Vaccine among U.S. Health Care Personnel, N Engl J Med, vol. 385, no. 25, p. e90, Dec 16 2021, https:\/\/doi.org\/10.1056\/NEJMoa2106599","DOI":"10.1056\/NEJMoa2106599"},{"key":"10345_CR11","doi-asserted-by":"publisher","unstructured":"Rosenberg ES et al. Covid-19 Vaccine Effectiveness in New York State. N Engl J Med, 386, 2, pp. 116\u201327, Jan 13 2022, https:\/\/doi.org\/10.1056\/NEJMoa2116063","DOI":"10.1056\/NEJMoa2116063"},{"key":"10345_CR12","doi-asserted-by":"publisher","unstructured":"Zhang Y, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18\u201359 years: a randomised, double-blind, placebo-controlled, phase 1\/2 clinical trial. Lancet Infect Dis. Feb 2021;21(2):181\u201392. https:\/\/doi.org\/10.1016\/S1473-3099(20)30843-4.","DOI":"10.1016\/S1473-3099(20)30843-4"},{"key":"10345_CR13","doi-asserted-by":"publisher","unstructured":"Voysey M et al. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK, Lancet, vol. 397, no. 10269, pp. 99\u2013111, Jan 9 2021, https:\/\/doi.org\/10.1016\/S0140-6736(20)32661-1","DOI":"10.1016\/S0140-6736(20)32661-1"},{"key":"10345_CR14","doi-asserted-by":"publisher","unstructured":"Thompson MG, et al. Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines. N Engl J Med. Jul 22 2021;385(4):320\u20139. https:\/\/doi.org\/10.1056\/NEJMoa2107058.","DOI":"10.1056\/NEJMoa2107058"},{"key":"10345_CR15","doi-asserted-by":"publisher","unstructured":"Ezzikouri S et al. Seroepidemiological assessment of SARS-CoV-2 vaccine responsiveness and associated factors in the vaccinated community of the Casablanca-Settat Region, Morocco, Sci Rep, vol. 14, no. 1, p. 7817, Apr 3 2024, https:\/\/doi.org\/10.1038\/s41598-024-58498-6","DOI":"10.1038\/s41598-024-58498-6"},{"key":"10345_CR16","doi-asserted-by":"publisher","unstructured":"Thomas SJ et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine through 6 Months. N Engl J Med, 385, 19, pp. 1761\u201373, Nov 4 2021, https:\/\/doi.org\/10.1056\/NEJMoa2110345","DOI":"10.1056\/NEJMoa2110345"},{"key":"10345_CR17","doi-asserted-by":"publisher","unstructured":"Yan ZP, Yang M, Lai CL. COVID-19 Vaccines: A Review of the Safety and Efficacy of Current Clinical Trials. Pharmaceuticals (Basel). Apr 25 2021;14(5). https:\/\/doi.org\/10.3390\/ph14050406.","DOI":"10.3390\/ph14050406"},{"key":"10345_CR18","doi-asserted-by":"publisher","unstructured":"Zeng G, et al. Immunogenicity and safety of a third dose of CoronaVac, and immune persistence of a two-dose schedule, in healthy adults: interim results from two single-centre, double-blind, randomised, placebo-controlled phase 2 clinical trials. Lancet Infect Dis. Apr 2022;22(4):483\u201395. https:\/\/doi.org\/10.1016\/S1473-3099(21)00681-2.","DOI":"10.1016\/S1473-3099(21)00681-2"},{"key":"10345_CR19","doi-asserted-by":"publisher","unstructured":"Chen Y, Zhao X, Zhou H, Zhu H, Jiang S, Wang P. Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. Nat Rev Immunol. Mar 2023;23(3):189\u201399. https:\/\/doi.org\/10.1038\/s41577-022-00784-3.","DOI":"10.1038\/s41577-022-00784-3"},{"key":"10345_CR20","doi-asserted-by":"publisher","unstructured":"English E, Cook LE, Piec I, Dervisevic S, Fraser WD, John WG. Performance of the Abbott SARS-CoV-2 IgG II Quantitative Antibody Assay Including the New Variants of Concern, VOC 202012\/V1 (United Kingdom) and VOC 202012\/V2 (South Africa), and First Steps towards Global Harmonization of COVID-19 Antibody Methods, J Clin Microbiol, vol. 59, no. 9, p. e0028821, Aug 18 2021, https:\/\/doi.org\/10.1128\/JCM.00288-21","DOI":"10.1128\/JCM.00288-21"},{"key":"10345_CR21","doi-asserted-by":"publisher","unstructured":"Ranjbar Kermani F, et al. Estimate of anti-SARS-CoV-2 spike IgG antibodies prevalence among Iranian population based on blood donations: A serial cross-sectional study during the third wave of the pandemic. Transfus Clin Biol. Feb 2023;30(1):123\u20139. https:\/\/doi.org\/10.1016\/j.tracli.2022.09.003.","DOI":"10.1016\/j.tracli.2022.09.003"},{"key":"10345_CR22","doi-asserted-by":"publisher","unstructured":"Bendavid E et al. COVID-19 antibody seroprevalence in Santa Clara County, California. Int J Epidemiol, 50, 2, pp. 410\u20139, May 17 2021, https:\/\/doi.org\/10.1093\/ije\/dyab010","DOI":"10.1093\/ije\/dyab010"},{"key":"10345_CR23","doi-asserted-by":"publisher","unstructured":"Zhang Y, et al. Real-world study of the effectiveness of BBIBP-CorV (Sinopharm) COVID-19 vaccine in the Kingdom of Morocco. BMC Public Health. Aug 20 2022;22(1):1584. https:\/\/doi.org\/10.1186\/s12889-022-14016-9.","DOI":"10.1186\/s12889-022-14016-9"},{"key":"10345_CR24","doi-asserted-by":"publisher","unstructured":"Assaid N, et al. Anti-SARS-CoV-2 Antibody Responses 5 Months Post Complete Vaccination of Moroccan Healthcare Workers. Vaccines (Basel). Mar 18 2022;10(3). https:\/\/doi.org\/10.3390\/vaccines10030465.","DOI":"10.3390\/vaccines10030465"},{"key":"10345_CR25","doi-asserted-by":"publisher","unstructured":"Amellal H, Assaid N, Akarid K, Maaroufi A, Ezzikouri S, Sarih M. Mix-and-match COVID-19 vaccines trigger high antibody response after the third dose vaccine in Moroccan health care workers. Vaccine X. Aug 2023;14:100288. https:\/\/doi.org\/10.1016\/j.jvacx.2023.100288.","DOI":"10.1016\/j.jvacx.2023.100288"},{"key":"10345_CR26","doi-asserted-by":"publisher","unstructured":"Sughayer MA et al. Comparison of the effectiveness and duration of anti-RBD SARS-CoV-2 IgG antibody response between different types of vaccines: Implications for vaccine strategies, Vaccine, vol. 40, no. 20, pp. 2841\u20132847, May 3 2022, https:\/\/doi.org\/10.1016\/j.vaccine.2022.03.069","DOI":"10.1016\/j.vaccine.2022.03.069"},{"key":"10345_CR27","doi-asserted-by":"publisher","unstructured":"Al Kaabi N et al. Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial, JAMA, vol. 326, no. 1, pp. 35\u201345, Jul 6 2021, https:\/\/doi.org\/10.1001\/jama.2021.8565","DOI":"10.1001\/jama.2021.8565"},{"key":"10345_CR28","doi-asserted-by":"publisher","unstructured":"Wheeler SE et al. Differential Antibody Response to mRNA COVID-19 Vaccines in Healthy Subjects, Microbiol Spectr, vol. 9, no. 1, p. e0034121, Sep 3 2021, https:\/\/doi.org\/10.1128\/Spectrum.00341-21","DOI":"10.1128\/Spectrum.00341-21"},{"key":"10345_CR29","doi-asserted-by":"publisher","unstructured":"Jones JM et al. Estimates of SARS-CoV-2 Seroprevalence and Incidence of Primary SARS-CoV-2 Infections Among Blood Donors, by COVID-19 Vaccination Status - United States, April 2021-September 2022. MMWR Morb Mortal Wkly Rep, 72, 22, pp. 601\u20135, Jun 2 2023, https:\/\/doi.org\/10.15585\/mmwr.mm7222a3","DOI":"10.15585\/mmwr.mm7222a3"},{"key":"10345_CR30","doi-asserted-by":"publisher","unstructured":"Badano MN, et al. Humoral response to the BBIBP-CorV vaccine over time in healthcare workers with or without exposure to SARS-CoV-2. Mol Immunol. Mar 2022;143:94\u20139. https:\/\/doi.org\/10.1016\/j.molimm.2022.01.009.","DOI":"10.1016\/j.molimm.2022.01.009"},{"key":"10345_CR31","doi-asserted-by":"publisher","unstructured":"Bates TA, et al. The time between vaccination and infection impacts immunity against SARS-CoV-2 variants. medRxiv Jan. 2023;4. https:\/\/doi.org\/10.1101\/2023.01.02.23284120.","DOI":"10.1101\/2023.01.02.23284120"},{"key":"10345_CR32","doi-asserted-by":"publisher","unstructured":"Moghnieh R et al. Immunogenicity and reactogenicity of BNT162b2 booster in BBIBP-CorV-vaccinated individuals compared with homologous BNT162b2 vaccination: Results of a pilot prospective cohort study from Lebanon, Vaccine, vol. 39, no. 46, pp. 6713\u20136719, Nov 5 2021, https:\/\/doi.org\/10.1016\/j.vaccine.2021.10.007","DOI":"10.1016\/j.vaccine.2021.10.007"},{"key":"10345_CR33","doi-asserted-by":"publisher","unstructured":"Barda N et al. Effectiveness of a third dose of the BNT162b2 mRNA COVID-19 vaccine for preventing severe outcomes in Israel: an observational study, Lancet, vol. 398, no. 10316, pp. 2093\u20132100, Dec 4 2021, https:\/\/doi.org\/10.1016\/S0140-6736(21)02249-2","DOI":"10.1016\/S0140-6736(21)02249-2"},{"key":"10345_CR34","doi-asserted-by":"publisher","unstructured":"Kontopoulou K, Nakas CT, Papazisis G. Significant Increase in Antibody Titers after the 3rd Booster Dose of the Pfizer-BioNTech mRNA COVID-19 Vaccine in Healthcare Workers in Greece, Vaccines (Basel), vol. 10, no. 6, May 30 2022, https:\/\/doi.org\/10.3390\/vaccines10060876","DOI":"10.3390\/vaccines10060876"},{"key":"10345_CR35","doi-asserted-by":"publisher","unstructured":"Hillus D, et al. Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study. Lancet Respir Med. Nov 2021;9(11):1255\u201365. https:\/\/doi.org\/10.1016\/S2213-2600(21)00357-X.","DOI":"10.1016\/S2213-2600(21)00357-X"},{"key":"10345_CR36","doi-asserted-by":"publisher","unstructured":"Gilbert PB et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial, Science, vol. 375, no. 6576, pp. 43\u201350, Jan 7 2022, https:\/\/doi.org\/10.1126\/science.abm3425","DOI":"10.1126\/science.abm3425"},{"key":"10345_CR37","doi-asserted-by":"publisher","unstructured":"Feng S et al. Correlates of protection against symptomatic and asymptomatic SARS-CoV-2 infection. Nat Med, 27, 11, pp. 2032\u201340, Nov 2021, https:\/\/doi.org\/10.1038\/s41591-021-01540-1","DOI":"10.1038\/s41591-021-01540-1"},{"key":"10345_CR38","doi-asserted-by":"publisher","unstructured":"Andrews N, et al. Effectiveness of COVID-19 booster vaccines against COVID-19-related symptoms, hospitalization and death in England. Nat Med. Apr 2022;28(4):831\u20137. https:\/\/doi.org\/10.1038\/s41591-022-01699-1.","DOI":"10.1038\/s41591-022-01699-1"},{"key":"10345_CR39","doi-asserted-by":"publisher","unstructured":"Adams K, et al. Vaccine Effectiveness of Primary Series and Booster Doses against Omicron Variant COVID-19-Associated Hospitalization in the United States. medRxiv Jun. 2022;14. https:\/\/doi.org\/10.1101\/2022.06.09.22276228.","DOI":"10.1101\/2022.06.09.22276228"},{"key":"10345_CR40","doi-asserted-by":"publisher","unstructured":"Wald A. Booster Vaccination to Reduce SARS-CoV-2 Transmission and Infection, JAMA, vol. 327, no. 4, pp. 327\u2013328, Jan 25 2022, https:\/\/doi.org\/10.1001\/jama.2021.23726","DOI":"10.1001\/jama.2021.23726"},{"key":"10345_CR41","doi-asserted-by":"publisher","unstructured":"Rydyznski Moderbacher C et al. Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity, Cell, vol. 183, no. 4, pp. 996\u20131012 e19, Nov 12., 2020, https:\/\/doi.org\/10.1016\/j.cell.2020.09.038","DOI":"10.1016\/j.cell.2020.09.038"},{"key":"10345_CR42","doi-asserted-by":"publisher","unstructured":"Goel RR et al. mRNA vaccines induce durable immune memory to SARS-CoV-2 and variants of concern, Science, vol. 374, no. 6572, p. abm0829, Dec 3 2021, https:\/\/doi.org\/10.1126\/science.abm0829","DOI":"10.1126\/science.abm0829"},{"key":"10345_CR43","doi-asserted-by":"publisher","unstructured":"Dan JM et al. Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection, Science, vol. 371, no. 6529, Feb 5 2021, https:\/\/doi.org\/10.1126\/science.abf4063","DOI":"10.1126\/science.abf4063"},{"key":"10345_CR44","doi-asserted-by":"publisher","unstructured":"Miyamoto S et al. Vaccination-infection interval determines cross-neutralization potency to SARS-CoV-2 Omicron after breakthrough infection by other variants, Med, vol. 3, no. 4, pp. 249\u2013261 e4, Apr 8 2022, https:\/\/doi.org\/10.1016\/j.medj.2022.02.006","DOI":"10.1016\/j.medj.2022.02.006"},{"key":"10345_CR45","doi-asserted-by":"publisher","unstructured":"Magen O, et al. Fourth Dose of BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Setting. N Engl J Med. Apr 28 2022;386:1603\u201314. https:\/\/doi.org\/10.1056\/NEJMoa2201688.","DOI":"10.1056\/NEJMoa2201688"},{"key":"10345_CR46","doi-asserted-by":"publisher","unstructured":"Grunau B et al. Immunogenicity of Extended mRNA SARS-CoV-2 Vaccine Dosing Intervals, JAMA, vol. 327, no. 3, pp. 279\u2013281, Jan 18 2022, https:\/\/doi.org\/10.1001\/jama.2021.21921","DOI":"10.1001\/jama.2021.21921"},{"key":"10345_CR47","doi-asserted-by":"publisher","unstructured":"Hall VG, et al. Delayed-interval BNT162b2 mRNA COVID-19 vaccination enhances humoral immunity and induces robust T cell responses. Nat Immunol. Mar 2022;23(3):380\u20135. https:\/\/doi.org\/10.1038\/s41590-021-01126-6.","DOI":"10.1038\/s41590-021-01126-6"},{"key":"10345_CR48","doi-asserted-by":"publisher","unstructured":"Payne RP et al. Immunogenicity of standard and extended dosing intervals of BNT162b2 mRNA vaccine, Cell, vol. 184, no. 23, pp. 5699\u20135714 e11, Nov 11 2021, https:\/\/doi.org\/10.1016\/j.cell.2021.10.011","DOI":"10.1016\/j.cell.2021.10.011"}],"container-title":["BMC Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-10345-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12879-024-10345-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12879-024-10345-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,28]],"date-time":"2024-12-28T20:01:54Z","timestamp":1735416114000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcinfectdis.biomedcentral.com\/articles\/10.1186\/s12879-024-10345-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,28]]},"references-count":48,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["10345"],"URL":"https:\/\/doi.org\/10.1186\/s12879-024-10345-9","relation":{},"ISSN":["1471-2334"],"issn-type":[{"value":"1471-2334","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,28]]},"assertion":[{"value":"13 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"was obtained from all participants involved in the study. For minors, the informed consent of a parent has been obtained.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}},{"value":"This study was conducted in accordance with the Declaration of Helsinki. The study was approved by the ethics committee of Ibn Rochd hospital in Casablanca (N\u00b001\/22).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Institutional review board statement"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1470"}}